Ecuador issues compulsory licence for Abbott's Kaletra
This article was originally published in Scrip
Abbott's antiretroviral Kaletra (lopinavir plus ritonavir) is facing generic competition in Ecuador after the government issued a compulsory licence, following a request from the ESKE Group, for ritonavir on 14 April. The R&D pharmaceutical industry has criticised the decision, saying it undermines the patent system.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.